## Bechara G Mfarrej

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6396667/publications.pdf

Version: 2024-02-01

279701 289141 1,675 47 23 40 citations g-index h-index papers 49 49 49 2940 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular products. Cytotherapy, 2021, 23, 77-87.	0.3	8
2	Related versus unrelated allogeneic HPC graft cryopreservation: a single-center experience in the context of the global COVID-19 pandemic. Bone Marrow Transplantation, 2021, 56, 2013-2015.	1.3	7
3	Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor. Cancers, 2021, 13, 2673.	1.7	12
4	Mobilization regimen, including Plerixafor, does not impact CD34 recovery after automated post-thaw processing. Cytotherapy, 2020, 22, S147.	0.3	0
5	Key role of macrophages in tolerance induction via T regulatory type 1 (Tr1) cells. Clinical and Experimental Immunology, 2020, 201, 222-230.	1.1	9
6	Validation of a flow cytometry-based method for quantitative viable lymphocyte- immunophenotyping in fresh and cryopreserved hematopoietic cellular products. Cytotherapy, 2020, 22, S155.	0.3	0
7	A matchedâ€pair analysis reveals marginally reduced CD34+ cell mobilization on second occasion in 27 related donors who underwent peripheral blood stem cell collection twice at the same institution. Transfusion, 2019, 59, 3442-3447.	0.8	4
8	Driving Medical Innovation Through Interdisciplinarity: Unique Opportunities and Challenges. Frontiers in Medicine, 2019, 6, 35.	1.2	10
9	From clinical proof-of-concept to commercialization of CAR T cells. Drug Discovery Today, 2018, 23, 758-762.	3.2	17
	750 702.		
10	The Path To Commercialize CAR-T Cell Products. , 2018, , .		0
10		0.4	0
	The Path To Commercialize CAR-T Cell Products. , 2018, , .  IL-10 Receptor Signaling Is Essential for TR1 Cell Function In Vivo. Journal of Immunology, 2017, 198,	0.4	
11	The Path To Commercialize CAR-T Cell Products., 2018,,.  IL-10 Receptor Signaling Is Essential for TR1 Cell Function In Vivo. Journal of Immunology, 2017, 198, 1130-1141.  Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in		108
11 12	The Path To Commercialize CAR-T Cell Products., 2018,,.  IL-10 Receptor Signaling Is Essential for TR1 Cell Function In Vivo. Journal of Immunology, 2017, 198, 1130-1141.  Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts. Cytotherapy, 2017, 19, 1501-1508.  Pre-clinical validation of Lovo for post-thaw DMSO depletion from cryopreserved stem cells.	0.3	108
11 12 13	The Path To Commercialize CAR-T Cell Products., 2018,,.  IL-10 Receptor Signaling Is Essential for TR1 Cell Function In Vivo. Journal of Immunology, 2017, 198, 1130-1141.  Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts. Cytotherapy, 2017, 19, 1501-1508.  Pre-clinical validation of Lovo for post-thaw DMSO depletion from cryopreserved stem cells. Cytotherapy, 2017, 19, 550.  Feasibility and safety of allogeneic ex vivo activated-NK cell infusion after matched related hematopoietic stem cell transplantation: Preliminary results of a prospective phase I trial.	0.3	108 13 0
11 12 13	The Path To Commercialize CAR-T Cell Products., 2018,,.  IL-10 Receptor Signaling Is Essential for TR1 Cell Function In Vivo. Journal of Immunology, 2017, 198, 1130-1141.  Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts. Cytotherapy, 2017, 19, 1501-1508.  Pre-clinical validation of Lovo for post-thaw DMSO depletion from cryopreserved stem cells. Cytotherapy, 2017, 19, S50.  Feasibility and safety of allogeneic ex vivo activated-NK cell infusion after matched related hematopoietic stem cell transplantation: Preliminary results of a prospective phase I trial. Cytotherapy, 2017, 19, S16.  Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased	0.3 0.3	108 13 0
11 12 13 14	The Path To Commercialize CAR-T Cell Products., 2018,,.  IL-10 Receptor Signaling Is Essential for TR1 Cell Function In Vivo. Journal of Immunology, 2017, 198, 1130-1141.  Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts. Cytotherapy, 2017, 19, 1501-1508.  Pre-clinical validation of Lovo for post-thaw DMSO depletion from cryopreserved stem cells. Cytotherapy, 2017, 19, 550.  Feasibility and safety of allogeneic ex vivo activated-NK cell infusion after matched related hematopoietic stem cell transplantation: Preliminary results of a prospective phase I trial. Cytotherapy, 2017, 19, S16.  Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression. Scientific Reports, 2017, 7, 6897.  Generation of donor-specific Tr1 cells to be used after kidney transplantation and definition of the timing of their in vivo infusion in the presence of immunosuppression. Journal of Translational	0.3 0.3 0.3	108 13 0 0 53

#	Article	IF	CITATIONS
19	Developing translational medicine professionals: the Marie SkÅ,odowska-Curie action model. Journal of Translational Medicine, 2016, 14, 329.	1.8	4
20	The "Unusual Suspects―in Allograft Rejection: Will T Regulatory Cell Therapy Arrest Them?. Current Transplantation Reports, 2016, 3, 221-226.	0.9	0
21	Generation of Donor-specific T Regulatory Type 1 Cells From Patients on Dialysis for Cell Therapy After Kidney Transplantation. Transplantation, 2015, 99, 1582-1589.	0.5	24
22	Glomerular Inflammation Correlates With Endothelial Injury and With IL-6 and IL- $1\hat{l}^2$ Secretion in the Peripheral Blood. Transplantation, 2014, 97, 1034-1042.	0.5	24
23	TIM-3 Regulates Innate Immune Cells To Induce Fetomaternal Tolerance. Journal of Immunology, 2013, 190, 88-96.	0.4	92
24	B7h (ICOS-L) Maintains Tolerance at the Fetomaternal Interface. American Journal of Pathology, 2013, 182, 2204-2213.	1.9	30
25	Decompression of Inflammatory Edema along with Endothelial Cell Therapy Expedites Regeneration after Renal Ischemia-Reperfusion Injury. Cell Transplantation, 2013, 22, 2091-2103.	1.2	9
26	Prolonged, Low-Dose Anti-Thymocyte Globulin, Combined with CTLA4-lg, Promotes Engraftment in a Stringent Transplant Model. PLoS ONE, 2013, 8, e53797.	1.1	12
27	Immune Profile of Pediatric Renal Transplant Recipients following Alemtuzumab Induction. Journal of the American Society of Nephrology: JASN, 2012, 23, 174-182.	3.0	30
28	Derivation and Validation of a Cytokine-Based Assay to Screen for Acute Rejection in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1018-1025.	2.2	32
29	Relief of the Renal Pressure after Ischemia-Reperfusion Injury Reduces the Inflammatory Response Within Ischemic Kidneys. Transplantation, 2012, 94, 261.	0.5	0
30	Critical Role of Proinflammatory Cytokine IL-6 in Allograft Rejection and Tolerance. American Journal of Transplantation, 2012, 12, 90-101.	2.6	93
31	Deleterious Effect of CTLA4-Ig on a Treg-Dependent Transplant Model. American Journal of Transplantation, 2012, 12, 846-855.	2.6	123
32	The Link between the PDL1 Costimulatory Pathway and Th17 in Fetomaternal Tolerance. Journal of Immunology, 2011, 187, 4530-4541.	0.4	145
33	Monocyte-Secreted Inflammatory Cytokines Are Associated With Transplant Glomerulopathy in Renal Allograft Recipients. Transplantation, 2011, 91, 552-559.	0.5	30
34	Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood, 2011, 117, 1176-1183.	0.6	43
35	Effect of biologic agents on regulatory T cells. Transplantation Reviews, 2011, 25, 110-116.	1.2	9
36	Determination of optimal incubation time for the production of acute phase cytokines ex vivo by peripheral blood mononuclear cells from renal transplant recipients. Journal of Immunological Methods, 2011, 366, 119-122.	0.6	4

#	Article	lF	CITATIONS
37	Anti-CD3 mAb treatment cures PDL1â^'/â^'.NOD mice of diabetes but precipitates fatal myocarditis. Clinical Immunology, 2011, 140, 47-53.	1.4	2
38	The Novel Role of SERPINB9 in Cytotoxic Protection of Human Mesenchymal Stem Cells. Journal of Immunology, 2011, 187, 2252-2260.	0.4	32
39	IL-21 Is an Antitolerogenic Cytokine of the Late-Phase Alloimmune Response. Diabetes, 2011, 60, 3223-3234.	0.3	26
40	Green Tea Epigallo-Catechin-Galleate Ameliorates the Development of Obliterative Airway Disease. Experimental Lung Research, 2011, 37, 435-444.	0.5	13
41	Dual-Kidney Transplants as an Alternative for Very Marginal Donors: Long-Term Follow-Up in 63 Patients. Transplantation, 2010, 90, 1125-1130.	0.5	34
42	Improved Function of Circulating Angiogenic Cells Is Evident in Type 1 Diabetic Islet-Transplanted Patients. American Journal of Transplantation, 2010, 10, 2690-2700.	2.6	22
43	TIM-3: A Novel Regulatory Molecule of Alloimmune Activation. Journal of Immunology, 2010, 185, 5806-5819.	0.4	69
44	Polylactideâ€cyclosporin A nanoparticles for targeted immunosuppression. FASEB Journal, 2010, 24, 3927-3938.	0.2	78
45	A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. Journal of Experimental Medicine, 2008, 205, 3133-3144.	4.2	277
46	Renin–angiotensin-system gene polymorphisms and depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1113-1118.	2.5	73
47	Sickle cell disease: the Lebanese experience. International Journal of Laboratory Hematology, 2007, 29, 399-408.	0.7	23